Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Using Remimazolam for Sedation in Patients After Heart Surgery

Official title: Remimazolam Besylate Versus Propofolfor Sedation of Postcardioperative Patients in Intensive Care Unit: a Prospective,Single-center,Randomized Non-inferior Trial

Run by First Affiliated Hospital of Zhejiang University · NCT06716840 · Data updated 2026-11-12

This study tests if a new sedative called remimazolam can help heart surgery patients recover better and get off breathing machines faster compared to a standard sedative.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment120 (estimated)
SponsorFirst Affiliated Hospital of Zhejiang University
Academic / other
Locations1 site (Hangzhou, Zhejiang)
StatusRecruiting
StartedFebruary 10, 2025
Main results expectedApril 30, 2025
Study endsMay 31, 2025
Registry record updatedFebruary 18, 2025
Trial IDNCT06716840 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 18 years old who have undergone cardiac surgery and require mechanical ventilation within 48 hours post-operation.

Probably not a fit

Patients who are pregnant, have certain cardiac conditions, or have a history of psychiatric illness may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of remimazolam besylate as a sedative for patients recovering from cardiac surgery who require mechanical ventilation. Participants aged 18 and older will be randomly assigned to receive either remimazolam or propofol for sedation, with the goal of achieving effective sedation while minimizing adverse effects and facilitating quicker extubation. The study aims to determine if remimazolam can provide a safer and more efficient sedation option compared to traditional sedatives.

Why it matters

Potential benefit: If successful, this study could lead to improved sedation practices in intensive care, enhancing recovery times for patients after cardiac surgery.

How similar studies have gone: While the use of remimazolam is relatively novel in this context, other studies have shown promising results with similar sedative approaches.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. age ≥ 18 years ;
2. admitted to the intensive care unit after cardiac surgery with techanical ventilation;
3. expected to extubation within 48hours ;
4. participant has given informed consent

Exclusion Criteria:

1. pregnant or lactating women
2. known or suspected hypersensitivity to the study drug
3. history of impaired consciousness or psychiatric illness
4. severe bradycardia with a heart rate of \< 50 beats per minute
5. systolic blood pressure \< 90 mmHg with fluid resuscitation and vasopressor maintenance
6. atrioventricular block(II or III degree), Left ventricular ejection fraction(LVEF) \<30%
7. participated in other clinical studies within 3 months

Where it's running

  • First afflilated hospital of zhejiang university school of medicine
    Hangzhou, Zhejiang, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.